Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NY-ESO-1 Positive”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT03697824
What this trial is testing

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

Who this might be right for
Neoplasms
GlaxoSmithKline
Testing effectiveness (Phase 2)Study completedNCT06703346
What this trial is testing

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Who this might be right for
Neoplasms
USWM CT, LLC 82
Very early researchEnded earlyNCT02774291
What this trial is testing

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Who this might be right for
HLA-A2 Positive Cells PresentMetastatic Malignant NeoplasmMetastatic Malignant Neoplasm in the Brain
Albert Einstein College of Medicine 3
Early research (Phase 1)Ended earlyNCT04526509
What this trial is testing

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Who this might be right for
Neoplasms
Adaptimmune 12